Shire plc and Shire Pharma Canada ULC announced the approval of Xiidra (lifitegrast ophthalmic solution 5%) for the treatment of dry eye disease in adults by Health Canada.
Xiidra is the first new prescription medication to treat dry eye disease in Canada in 7 years, according to a company news release.
The drug blocks the interaction between two types of proteins that cause inflammation, and its approval is supported by four safety and efficacy trials in which Xiidra improved dry eye symptoms as measured by eye dryness scores. In three (Read more...)
Uncategorized